Can the biomolecular corona induce an allergic reaction?-A proof-of-concept study. Biointerphases Muehe, A., Nejadnik, H., Muehe, H., Rosenberg, J., Gharibi, H., Saei, A. A., Lyu, S., Nadeau, K. C., Mahmoudi, M., Daldrup-Link, H. E. 2021; 16 (1): 011008


Ferumoxytol nanoparticles are being used clinically for the treatment of anemia and molecular imaging in patients. It is well documented that while most patients tolerate ferumoxytol well, a small percentage of patients (i.e., 0.01%) develop severe allergic reactions. The purpose of our proof-of-concept study was to determine whether patients with or without hypersensitivity reactions have specific protein corona profiles around ferumoxytol nanoparticles. In a retrospective, institutional review board approved pilot study, we enrolled 13 pediatric patients (5 girls, 8 boys, mean age 16.9±8.2 years) who received a ferumoxytol-enhanced magnetic resonance imaging and who did (group 1, n=5) or did not (group 2, n=8) develop an allergic reaction. Blood samples of these patients were incubated with ferumoxytol, and the formation of a hard protein corona around ferumoxytol nanoparticles was measured by dynamic light scattering, zeta potential, and liquid chromatography-mass spectrometry. We also performed in vitro immune response analyses to randomly selected coronas from each group. Our results provide preliminary evidence that ex vivo analysis of the biomolecular corona may provide useful and predictive information on the possibility of severe allergic reactions to ferumoxytol nanoparticles. In the future, patients with predisposition of an allergic reaction to ferumoxytol may be diagnosed based on the proteomic patterns of the corona around ferumoxytol in their blood sample.

View details for DOI 10.1116/6.0000755

View details for PubMedID 33706522